Shots:
- The US FDA has granted RMAT designation to GLPG5101 for the r/r mantle cell lymphoma (MCL)
- Designation was supported by P-I/II (ATALANTA-1) trial assessing GLPG5101 [50×106 (DL1), 110×106 (DL2) & 250×106 (DL3)] in r/r B-cell Non-Hodgkin Lymphoma pts, incl. those with MCL
- Trial demonstrated superior ORR & CR rate as well as favorable safety profile, with low rates of high-grade CRS, ICANS, & minimal dropout; further data to be shared in future
Ref: Galapagos | Image: Galapagos | Press Release
Related News:- Innovent Reports the US FDA’s IND Clearance of IBI3032 for Cardiometabolic Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
